Ceryvyn Therapeutics Limited (CKDXF)
OTC Markets OTCPK
Price as at 30 Sept 2026, 17:03 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Ceryvyn Therapeutics Limited trades at $0.01. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About Ceryvyn Therapeutics Limited
Ceryvyn Therapeutics Limited, a biopharmaceutical company, develops biologic therapy for the rare disease lymphangioleiomyomatosis in Australia. The company offers CYV-101, which is in pre-clinical trial stage, an inhaled therapy intended for delivery directly to the lung. It serves the biotechnology and healthcare industries. The company was formerly known as Opthea Limited and changed its name to Ceryvyn Therapeutics Limited in July 2026. Ceryvyn Therapeutics Limited was incorporated in 1984 and is headquartered in Hawthorn East, Australia.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Common questions
Where does SteadyShares get its CKDXF data?
Fundamentals for CKDXF come from company filings and exchange data, as listed on OTC Markets OTCPK; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 17:03 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for CKDXF, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.